ClinicalTrials.gg
CompletedNCT01589289Nidiag-NeuroUpdated Jan 18, 2016

Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC

A Phase 3 interventional study of Immunochromatographic HAT tests (DSD) and Card Agglutination Trypanosoma Test in Neurological Disorders, Cerebral Malaria and Bacterial Meningitis, sponsored by Institute of Tropical Medicine, Belgium. Completed at 1 site in Congo, The Democratic Republic of the. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2016-01-18.

Sponsored by Institute of Tropical Medicine, Belgium · Phase 3, Interventional, and Diagnostic

Phase
Phase 3
Study type
Interventional
Enrollment
352
Allocation
Not applicable
Ages
5 Years and older
Sex
All
01

Study summary

The impact of neurological disorders is enormous worldwide, and it is increased in poor settings, due to lack of diagnosis and treatment facilities as well as delayed management. In sub-Saharan Africa, the few observational studies conducted for the past 20 years show that neurological disorders accounted for 7 to 24% of all admissions. Central nervous system (CNS) infections were suspected in one third of all patients admitted with neurological symptoms, with a specific microbial aetiology identified in half of these. Most CNS infections may be considered as "severe and treatable diseases", e.g. human African trypanosomiasis (HAT), cerebral malaria, bacterial meningitis, CNS tuberculosis etc. If left untreated, death or serious sequels occur (mortality rates were as high as 30% in the above mentioned studies), but the outcome may be favourable with timely and appropriate management.

In poor settings, such conditions should be targeted in priority in the clinical decision-making process. Unfortunately, most neuro-infections present with non-specific symptoms in their early stages, leading to important diagnostic delays. Moreover, they require advanced diagnostic technology, which is not available in most tropical rural settings: here, you have to rely on clinical judgment and first-line laboratory results, whose confirming or excluding powers are limited or unknown. Several rapid diagnostic tests (RDTs) have been recently developed for conditions like malaria or HIV, but their diagnostic contribution has not been evaluated within a multi-disease approach.

Thus, this research aims at improving the early diagnosis of severe and treatable neglected and non-neglected infectious diseases which present with neurological symptoms in the province of Bandundu, Democratic Republic of Congo (DRC), by combining classic clinical predictors with a panel of simple point-of-care rapid diagnostic tests.

The evaluation of existing algorithms and elaboration/validation of new guidelines will be described in a subsequent protocol.

Read the detailed description

The impact of neurological disorders is enormous in terms of mortality, morbidity, physical disability and psychological distress, and it is increased in low-resource settings by lack of diagnosis and of treatment facilities as well as delayed management. The frequency of neurological disorders and the pattern of causative conditions are little documented in low-resource primary care settings.In sub-Saharan Africa, the few observational studies conducted for the past 20 years, show that neurological disorders accounted for 7 to 24% of all admissions. Central nervous system (CNS) infections were suspected in one third of all patients admitted with neurological symptoms, with a specific microbial aetiology identified in half of these. Where it has been investigated, up to one third of neurological admissions was related to HIV infection in some settings. Neuro-infections were also the leading aetiologies of common neurological symptoms (such as headache) in African HIV-positive patients, and autopsy studies have demonstrated that CNS infections accounted for 20% of the causes of death in HIV-positive individuals in sub-Saharan Africa.

Most CNS infections may be considered as "severe and treatable diseases", e.g. human African trypanosomiasis (HAT), cerebral malaria, bacterial meningitis, CNS tuberculosis, neurosyphilis, cryptococcal meningitis or toxoplasma encephalitis etc. If left untreated, death or serious sequels usually occur; mortality rates of neurological admissions were as high as 30% in the above mentioned studies. However, outcome may be favourable with timely and appropriate management.

In resource-constrained settings more than elsewhere, such "severe and treatable" conditions should be targeted in priority in the clinical decision-making process. Unfortunately, most neuro-infections present with non-specific symptoms in their early stages, leading to important diagnostic delays. Moreover, neurological diagnoses frequently require advanced technology, but this is far beyond reach of most tropical rural settings, where you have to rely on clinical judgment and first-line laboratory results. However, the confirming or excluding powers of most clinical and laboratory features are limited or have never been adequately quantified, in particular in settings lacking reference diagnostic methods. Several rapid diagnostic tests (RDTs) have been developed in the last decade for conditions like malaria or HIV infection, but their diagnostic contribution has never been evaluated within a multi-disease approach. Most CNS infections with worldwide distribution affect disproportionally the (sub)-tropical regions, while others are restricted to the tropics. Also, many infections with potential neuropathogenicity belong to the group of 17 Neglected Tropical Diseases (NTDs) on which attention has been recently brought. As said above, most of them may be considered as "severe and treatable"; however, in most tropical settings, epidemiology of NTDs and other infectious diseases (IDs) is largely unknown, seriously impairing the case finding and clinical decision-making.

The aim of this research therefore is to improve the early diagnosis of severe and treatable neglected and non-neglected infectious diseases which may present with neurological symptoms in the province of Bandundu, Democratic Republic of Congo (DRC). This will be achieved through the elaboration and validation of new diagnostic guidelines based on epidemiological evidence, combining classic clinical predictors with a panel of simple point-of-care rapid diagnostic tests, and designed with a "panoramic" (not-to-miss) approach.

In particular, the investigators hope to determine the pre-test probability of HAT and other priority neglected tropical diseases/infectious diseases in patients presenting with neurological disorders; to assess the predictive weight of clinical and first-line laboratory features in the diagnosis of HAT and other priority NTDs/IDs; to assess the sensitivity, specificity and predictive values of novel point-of-care RDTs for the diagnosis of HAT and other priority NTDs/IDs in patients with neurological disorders; and to assess the diagnostic performances of combinations of novel and existing RDTs for diagnosing HAT and other priority NTDs/IDs in patients with neurological disorders. Enrolled patients will be managed according the current standard of care in Bandundu, DRC and with the treatments locally available through health facilities/programs.

The objectives and methodology of this second step of our research (evaluation of existing algorithms and elaboration/validation of new guidelines) will be described in a subsequent protocol. Another similar study (described in another protocol) will be conducted in parallel to explore the aetiologies of prolonged fever in the same setting.

02

Conditions studied

  • Neurological Disorders
  • Cerebral Malaria
  • Bacterial Meningitis
  • Central Nervous System Tuberculosis
  • Neurosyphilis
  • Cryptococcal Meningitis

Keywords

  • Diagnostic research
  • Rapid diagnostic tests
  • Neurological disorders
  • Neglected Tropical Diseases
  • Developing countries
03

In context

Nervous System Diseases

757 studies on the registry are indexed under Nervous System Diseases; 218 are open to participants now.

This study's enrollment of 352 is above the median of 55 across 495 interventional studies indexed under Nervous System Diseases.

Browse Nervous System Diseases studies →

Lead sponsor

Institute of Tropical Medicine, Belgium is the lead sponsor of 104 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients > 5 years-old AND
  • Altered state of consciousness (confusion to coma) OR/AND
  • Changes of sleep pattern (daytime slumber, night insomnia)OR/AND
  • Cognitive decline OR/AND
  • Changes in personality/behaviour (e.g. bouts of mania)OR/AND
  • Epileptic seizure(s)OR/AND
  • Daily severe/progressive headache OR/AND
  • Meningismus (headache, neck stiffness, nausea/vomiting, photophobia)
  • Cranial nerve lesions OR/AND
  • Sensory-motor deficits or other focal neurological signs (e.g. dysphagia, dysarthria, ataxia, dystonia,...)OR/AND
  • Gait disorders (e.g. spastic or ataxic gait)

Exclusion criteria

Exclusion Criteria:

  • Those unwilling or unable to give written (either directly or via proxy)
  • Those unable in the physician's opinion to comply with the study requirements
  • Neurological symptom unequivocally related with recent trauma
  • Neurological symptom as sequelae of previous well-established neurological events (e.g. stroke,...)
  • First seizure below 6 years of age (early onset seizure)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
352 participants (actual)

Study arms

  • Experimental
    Phase 3 RDTs

    The different interventions will be assessed for estimation of sensitivity, specificity and predictive values in the patients' cohort, for the respective target conditions. \[To be noted that, in addition, also the predictive values of validated RDTs when used alone and in various combinations will be estimated\].

    Device: Immunochromatographic HAT tests (DSD) · Device: Card Agglutination Trypanosoma Test · Device: TB POC Nucleic Acid Amplification Test (Molbio Diagnostics) · Device: TB 3-marker RDT (Tulip diagnostics) · Device: Cryptococcal Antigen Lateral Flow Assay (Immy)

Interventions

  • DeviceImmunochromatographic HAT tests (DSD)

    Immunochromatographic HAT diagnostic tests manufactured by DSD, Korea and FIND

  • DeviceCard Agglutination Trypanosoma Test

    Card Agglutination Trypanosoma Test on whole blood and as dilution

    Also known as: CATT

  • DeviceTB POC Nucleic Acid Amplification Test (Molbio Diagnostics)

    TB POC Nucleic Acid Amplification Test: "microPCR handheld device" (Molbio Diagnostics PVT ltd, India)

    Also known as: NAAT

  • DeviceTB 3-marker RDT (Tulip diagnostics)

    TB 3-marker RDT: ADA2/IFN-g/LAM (Tulip diagnostics, ltd, India) - pending availability for phase 3 validation

  • DeviceCryptococcal Antigen Lateral Flow Assay (Immy)

    Cryptococcal Antigen Lateral Flow Assay (Immy, USA)

    Also known as: CrAg-LAT

06

What researchers measure

Primary outcomes

  1. Prevalence of HAT and other NTDs/IDs

    Number of patients diagnosed with HAT and other NTDs/IDs among those presenting with neurological disorders in rural hospitals of Bandundu, DRC (pre-test probability)

    Time frame: 18 months

  2. Identification of reliable diagnostic tests

    Assessment of the sensitivity, likelihood ratios and performances (diagnostic accuracy) of the novel study RDTs for the respective target conditions, and identification of those that should be included in future diagnostic protocols

    Time frame: 18 months

  3. Predictive values of RDTs

    Predictive values (post-test probabilities) of novel and existing RDTs, alone and in combination, for the respective target conditions within this multi-disease approach

    Time frame: 18 months

  4. Identification of clinical and laboratory diagnostic indicators

    Assessment of the specificity of the different clinical and first-line laboratory features for the diagnosis of HAT and other priority NTDs/IDs in the setting, for determining those that should be included in future diagnostic protocols

    Time frame: 18 months

Secondary outcomes

  1. Cure rate

    Number of patients who positively respond to specific/empirical therapies, as assessed as final patient outcomes (cure, referral, sequelae, death)

    Time frame: 18 months

  2. Cost-effectiveness of the diagnostic tests

    Unit costs of diagnostic tests for the diagnosis of HAT and other priority NTDs/IDs in the setting

    Time frame: 18 months

07

Study locations

1 site
  • Reference Hospital Mosango
    Mosango, Bandundu, Congo, The Democratic Republic of the
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Jan 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2012
First posted
May 1, 2012
Start
Sep 2012
Primary completionActual
Jan 2015
CompletionActual
May 2015
Last update
Jan 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01589289
Collaborators
Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo, University Hospital, Geneva
Responsible party
Sponsor
First posted
May 1, 2012
Start date
Sep 2012
Primary completion
Jan 2015
Completion
May 2015
Last update
Jan 18, 2016

Study contacts

Emmanuel Bottieau, MD
study director · ITM
Marleen Boelaert, MD, PhD
study chair · ITM

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion